Biological outcome measurements for behavioral interventions in multiple sclerosis [0.03%]
多发性硬化症行为干预的生物结局测量指标
Anja Fischer,Christoph Heesen,Stefan M Gold
Anja Fischer
Behavioral interventions including exercise, stress management, patient education, psychotherapy and multidisciplinary neurorehabilitation in general are receiving increasing recognition in multiple sclerosis (MS) clinical practice and rese...
Daniela Galimberti,Elio Scarpini
Daniela Galimberti
The first drugs developed for Alzheimer's disease (AD), acetylcholinesterase inhibitors (AChEI), increase acetylcholine levels, previously demonstrated to be reduced in AD. To date, four AChEI are approved for the treatment of mild-to-moder...
Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy [0.03%]
慢性炎症性脱髓鞘多发神经根病的标准化及升级治疗
Min-Suk Yoon,Andrew Chan,Ralf Gold
Min-Suk Yoon
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired, immune-mediated polyradiculoneuritis that is progressive or relapsing over a period of at least 8 weeks. Although the exact pathogenesis is unclear, it is thought to b...
Alexandre R Bisdorff
Alexandre R Bisdorff
Vestibular migraine is considered to be the second most common cause of vertigo and the most common cause of spontaneous episodic vertigo. The duration of attacks varies from seconds to days, usually lasting minutes to hours, and they mostl...
Nonconvulsive status epilepticus: a diagnostic and therapeutic challenge in the intensive care setting [0.03%]
重症监护环境下的非惊厥性连续状态癫痫：诊断与治疗的挑战
Martin Holtkamp,Hartmut Meierkord
Martin Holtkamp
Nonconvulsive status epilepticus (NCSE) comprises a group of syndromes that display a great diversity regarding response to anticonvulsants ranging from virtually self-limiting variants to entirely refractory forms. Therefore, treatment on ...
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice [0.03%]
多发性硬化对症治疗的临床实践中的多模式方法综述
João Carlos Correia de Sa,Laura Airas,Emmanuel Bartholome et al.
João Carlos Correia de Sa et al.
As more investigations into factors affecting the quality of life of patients with multiple sclerosis (MS) are undertaken, it is becoming increasingly apparent that certain comorbidities and associated symptoms commonly found in these patie...
Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis [0.03%]
视神经炎的临床诊治：陷阱、危险信号和鉴别诊断
Elke Voss,Peter Raab,Corinna Trebst et al.
Elke Voss et al.
Demyelinating optic neuritis (ON) is the most common cause of optic neuropathy typically presenting with a subacute painful visual loss. In 20% of patients with multiple sclerosis (MS), ON is the presenting symptom and half of the patients ...
Nicolas Collongues,Jérôme de Seze
Nicolas Collongues
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system (CNS) characterized by severe attacks of optic neuritis and myelitis, and which, unlike multiple sclerosis (MS), commonly spares the brain in the early stag...
Treatment of walking impairment in multiple sclerosis with dalfampridine [0.03%]
达酚美哌啶治疗多发性硬化症患者的步行功能障碍
Andrew R Blight
Andrew R Blight
Potassium channel blockade has long been considered a potential therapeutic strategy for treatment of multiple sclerosis (MS) based on the pathophysiology of demyelinated axons. Dalfampridine, which is also known as fampridine or 4-aminopyr...
Teresa C Frohman,Wanda Castro,Anjali Shah et al.
Teresa C Frohman et al.
Multiple sclerosis is the most common disabling neurological disease of young adults. The ability to impact the quality of life of patients with multiple sclerosis should not only incorporate therapies that are disease modifying, but should...